By: Jonathan Block
Pgiam BTIG has initiated Nektar Therapeutics ( NASDAQ: NKTR ) with a buy rating, citing the potential of rezpegaldesleukin, a potential
Managing Editor, Senior Health Care News Editor
Jonathan Block is the Managing Editor and Senior Health Care News Editor at Seeking Alpha. With a Master's in Public Health from CUNY Graduate School of Public Health, he brings expertise in the healthcare sector to his writing. His articles cover a wide range of topics, including stock analysis, market trends, and industry news.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jonathan Block's coverage focuses on investment analysis, press releases, and data citations related to sales & marketing and automotive industries. He would likely be interested in pitches that provide in-depth analysis of stock performance, company news, and market trends within these sectors.
Given his focus on investment analysis and citation of data, Jonathan may find value in pitches from financial experts who can offer unique insights into the potential impact of various factors on stock performance or industry trends.
While Jonathan does not have a specific geographic focus mentioned but given the nature of his articles focusing mainly on companies listed in US stock exchanges (NASDAQ: HAS; NYSE: MTN), it is safe to assume he has an interest primarily in the US market.
This information evolves through artificial intelligence and human feedback. Improve this profile .